Valmet increases Yusen Groups’s production capacity for high-quality tissue with three additional IntelliTissue machines

Valmet has been awarded an order to supply three IntelliTissue 1600 machines to Yusen Group for mills in Tai'an (Liaoning) and Chongxin (Gansu), the fourth consecutive order from Yusen and following nine prior IntelliTissue start‑ups; the order is booked in Valmet's Q1 2026 orders and start‑ups are scheduled for end‑2026 to early‑2027. Each line is 3,500 mm wide, designed for 1,650 m/min with ~30,000 tonnes annual capacity per machine (10–25 g/m² basis weight), supporting Yusen's push into high‑end facial and toilet tissue for the Chinese domestic market; the monetary value was not disclosed.

Analysis

Market structure: This win is a direct revenue and aftermarket-service boost to Valmet (Helsinki: VALMT) and strengthens Yusen’s ability to take share in China’s premium tissue segment; three IntelliTissue 1600 lines add ~90,000 t/year capacity (3×30kt) with start‑ups end‑2026/early‑2027, roughly ~1% of China’s tissue market — meaningful at the premium end. Competing tissue‑machine vendors (e.g., ANDR on VIE) and incumbent premium brand sellers in China (KMB, PG) face incremental pricing and share pressure in that window.

Risk assessment: Tail risks include China permitting/environmental clampdowns, ramp‑up failures causing months of lost production, and a sharp rise in pulp or energy costs that erodes margins; any of these would flip returns quickly. Effects are negligible in days, material across months as machines are commissioned, and crystallize over 12–36 months as capacity feeds through; hidden dependencies include local service capacity, spare‑parts supply chains, and steam/energy infrastructure.

Trade implications: Tactical trades should target Valmet’s recurring service and orderbook re‑rating (buy 12–18 month calls or call spreads) and exploit relative weakness in other machine vendors via a long VALMT / short ANDR pair; modest long exposure to pulp (futures) hedges raw‑material tightness. Sector tilt: overweight European industrials (machinery) and selective short exposure to multinational consumer staples with China premium exposure; re‑rate windows are Q1–Q4 2026 order disclosures and late‑2026 machine start‑ups.

Contrarian angles: The market underestimates high‑margin aftermarket and start‑up service revenue (20–30% incremental margin lift vs. equipment sale) and the speed at which a repeat customer like Yusen can scale; conversely, consensus underestimates oversupply risk — historical paper cycles show multi‑year price erosion after clustered investments. Unintended consequences include faster commoditization of mid‑tier tissue and potential regulatory-driven plant idling that could reverse benefits quickly.

Key Decisions for Investors

• Establish a 2–3% long position in Valmet (HEL:VALMT) using a 12–18 month call spread (buy 12–18m ATM call, sell a higher strike) within 2–4 weeks to capture orderbook and aftermarket revenue; take profits if position rises 25–35% or cut to 1% if position falls 20%.
• Initiate a 1% long VALMT / 1% short ANDR (VIE:ANDR) pair trade to capture machinery‑market share shift; rebalance after Valmet’s Q1 2026 order release and exit if ANDR wins two comparable large tissue contracts within 6 months.
• Allocate 0.5–1% to softwood pulp exposure (NBSK pulp futures or equivalent) to hedge incremental fiber demand from ~90kt new tissue capacity; trim if pulp prices appreciate >15% or by Jan 2027 if start‑ups are delayed.
• Trim 1–2% aggregate exposure to US staples with high China premium exposure (e.g., KMB, PG) over the next 3–9 months and hedge remaining China revenue exposure if Chinese tissue retail price spreads compress by >5% versus global averages.